Small molecule inhibitors that mimic the BH3 domain and specifically bind to anti-apoptotic Bcl-2 proteins can disrupt this protein–protein interaction, resulting in apoptosis activation in cancer cells [19]. The gene discussed is BCL2; the disease is cancer.